Miners were grated, tech lost its flavour and investors reached for defensive stocks as the ASX endured a distinctly pongy session.
It’s Hammer time as investors chase copper-laden explorers with advanced projects capable of plugging future supply gaps as the world wires up.
AnteoTech is taking aim at the multi-billion-dollar diagnostics market, with its proprietary bioconjugation technology designed to boost the performance and reliability of next-generation diagnostic tests.
Justin speaks with Dr Bronwyn Darlington, founder and CEO of Agscent, an Australian deep-tech company using AI, nano-sensors and more.
Brokers, experts and analysts are growing more optimistic by the day on the outlook for uranium, pulling ASX juniors along for the ride.
Emyria is among ASX healthcare companies securing government and insurer support to unlock predictable, scalable revenue streams.
